Product Description
a nonsteroidal anti-inflammatory drug (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17163285/)
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Philippines | Poland | Russia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Miosis | Pain Unspecified | Pain, Postoperative | Cataract
Known Adverse Events: Inflammation | Capsule Opacification
Company: Zyla Life Sciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, France, Germany, Italy, Russia, Spain
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Acute Pain|Low Back Pain|Pain, Postoperative|Renal Colic|Urinary Tract Infections
Phase 2: Conjunctivitis, Bacterial
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021/0376/HP | P3 |
Unknown Status |
Urinary Tract Infections |
2027-06-01 |
|
| NOV-1776-CL-101 | P1 |
Not yet recruiting |
Acute Pain |
2024-12-01 |
|
| MIRAKLE | P2 |
Completed |
Conjunctivitis, Bacterial |
2023-06-14 |
|
| NTM-001-AHC001 | P1 |
Completed |
Healthy Volunteers |
2022-07-05 |
28% |